While we did not have data on tumor grade and HER2 status, which was only routinely assessed in period 3 in our centers (2006 and onwards), it is unlikely that tumor biology would have changed substantially over the three periods to have a meaningful impact on our study results. The gene discussed is ERBB2; the disease is neoplasm.